Biologics for chronic plaque psoriasis

Researchers have investigated biologics for chronic plaque psoriasis and major adverse cardiovascular events (MACEs)

The researchers selected 22 randomised, controlled, double-blind monotherapy studies of IL-12/23 antibodies and anti-TNF-alpha agents in adults. Analysis of patients on anti-IL12/23 revealed that 10 out of 3,179 experienced a MACE, compared with none of the 1,474 patients on placebo. One of the 3,858 patients on anti-TNF-alpha agents experienced a MACE, compared with one of the 1,812 patients on placebo. The authors conclude there was no significant difference in the rate of MACEs in patients treated with biologics compared with placebo.
Ryan C, Leonardi CL, James G et al. JAMA 2011; 306: 864-71


Read these next

Dimethyl fumarate in patients with psoriasis

Psoriasis is associated with persistent and maintained...

1.5 CPD credits: Management of chronic plaque psoriasis

Therapeutics have improved, especially with new biological...

Management of scalp psoriasis in primary care

Management of scalp psoriasis in primary care

Patients will be better motivated to persist with treatment...


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases